Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation
· Approval by Swissmedic[1] enables highly sensitized patients in Switzerland to receive Idefirix[®] treatment prior to kidney transplantation · Idefirix[®] is now granted marketing authorization within the EU, the U.K.*, Israel and Switzerland Lund, Sweden May 13, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today announces that the Swiss Agency for Therapeutic Products (Swissmedic) has granted temporary marketing authorization for Idefirix[®] in adult patients with a positive crossmatch against an